RT Journal Article SR Electronic T1 Epigenetic clock acceleration is linked to age-at-onset of idiopathic and LRRK2 Parkinson’s disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.02.04.22270486 DO 10.1101/2022.02.04.22270486 A1 Tang, Xuelin A1 Gonzalez-Latapi, Paulina A1 Marras, Connie A1 Visanji, Naomi P. A1 Yang, Wanli A1 Sato, Christine A1 Lang, Anthony E. A1 Rogaeva, Ekaterina A1 Zhang, Ming YR 2022 UL http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270486.abstract AB Parkinson’s disease is a clinically and genetically heterogeneous movement disorder with highly variable age-at-onset. DNA methylation (DNAm) age is an epigenetic clock that could reflect biological aging. Studies of DNAm-age acceleration (difference between DNAm-age and chronological age) are pertinent to neurodegenerative diseases (e.g., Parkinson’s disease), for which aging is the strongest risk-factor. We assessed DNAm-age in idiopathic Parkinson’s disease (n=96) and a longitudinal LRRK2 cohort at four time-points over a 3-year period (n=220), including manifesting (n=91) and non-manifesting (n=129) G2019S-carriers. A highly variable age-at-onset was observed in both the idiopathic cohort (26-77 years) and manifesting G2019S-carriers (39-79 years). Increased DNAm-age acceleration was significantly associated with younger onset in idiopathic and LRRK2-related Parkinson’s disease, suggesting that every 5-year increase in DNAm-age acceleration is linked to about 6-year earlier onset. At an individual level, DNAm-age acceleration remained steady over a 3-year period for most G2019S-carriers, indicating that it might serve as a stable biomarker of biological aging. Future studies should evaluate the stability of DNAm-age acceleration over longer time-periods, especially for phenoconverters from non-manifesting to manifesting subjects. In conclusion, DNAm-age acceleration is linked to disease onset, and could be used in disease-modifying clinical trials of prodromal Parkinson’s disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (82071430) (MZ), the Fundamental Research Funds for the Central Universities (MZ), the Canadian Consortium on Neurodegeneration in Aging (ER), the Blidner Family Foundation (NPV), the McLaughlin Accelerator Grants in Genomic Medicine, and Robert L. Cunningham Parkinson's Research Award Foundations (ER, AEL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University Health Network Research Ethics Board approved for this work (UHN-REB 08-0615-AE).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.